Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Upadacitinib retreatment was safe and effective in patients who had treatment withdrawn.
Format: Microsoft PowerPoint (.ppt)
File Size: 192 KB
Released: July 27, 2020


Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

This educational activity is supported by educational grants from
Pfizer Inc.

Related Content

Results from subgroup analysis analyzing the efficacy, safety of dupilumab with or without concomitant TCS in patients with erythrodermic AD, from CCO

Released: July 27, 2020

Efficacy, safety of baricitinib in patients with 1 or more atopic comorbidity at baseline in BREEZE-AD1 and BREEZE-AD2, from CCO

Released: July 27, 2020

Efficacy, safety of once-daily oral abrocitinib 200 mg and 100 mg vs placebo in patients aged ≥12 years with moderate to severe AD; atopic dermatitis conference coverage from CCO

Released: July 20, 2020

An investigation of the efficacy and safety of dupilumab and concomitant topical corticosteroids in children aged ≥ 6 to < 12 years with severe AD: atopic dermatitis conference coverage from CCO

Released: July 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?